[{"id":"e230d360-a6b9-4645-ba83-bf51b7d847f6","acronym":"OncoACP-3","url":"https://clinicaltrials.gov/study/NCT06840535","created_at":"2025-02-25T13:44:03.457Z","updated_at":"2025-02-25T13:44:03.457Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients with Prostate Cancer","source_id_and_acronym":"NCT06840535 - OncoACP-3","lead_sponsor":"Philogen S.p.A.","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 02/01/2025","start_date":" 02/01/2025","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-21"},{"id":"76aa94db-cfe6-4048-bc32-6320bef5309a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06827080","created_at":"2025-02-25T14:44:58.708Z","updated_at":"2025-02-25T14:44:58.708Z","phase":"Phase 1/2","brief_title":"Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT06827080","lead_sponsor":"Zhengguo Chen","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 02/11/2025","start_date":" 02/11/2025","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-14"},{"id":"0200c541-08b4-4007-9e50-7da7eaed466e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05324332","created_at":"2025-02-26T11:41:22.043Z","updated_at":"2025-02-26T11:41:22.043Z","phase":"","brief_title":"68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients","source_id_and_acronym":"NCT05324332","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 04/15/2022","start_date":" 04/15/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2024-11-27"},{"id":"f93bea8a-4ae1-4cd6-ae81-5b0519b817f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06521775","created_at":"2025-02-27T07:54:44.561Z","updated_at":"2025-02-27T07:54:44.561Z","phase":"Phase 2","brief_title":"An Investigational Scan (Ga-68 PSMA-11 PET/CT) for the Detection of Therapy Response in Patients with Metastatic Adenoid Cystic Carcinoma","source_id_and_acronym":"NCT06521775","lead_sponsor":"Mayo Clinic","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 5","initiation":"Initiation: 08/12/2024","start_date":" 08/12/2024","primary_txt":" Primary completion: 08/12/2025","primary_completion_date":" 08/12/2025","study_txt":" Completion: 08/12/2025","study_completion_date":" 08/12/2025","last_update_posted":"2024-09-23"},{"id":"5c645a31-d350-4231-926f-0a8a1ea0892f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04573231","created_at":"2021-01-18T21:50:12.443Z","updated_at":"2024-07-02T16:35:02.152Z","phase":"Phase 2","brief_title":"Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer","source_id_and_acronym":"NCT04573231","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" HER-2 • FOLH1","pipe":" | ","alterations":" HER-2 negative • AR expression • FOLH1 expression","tags":["HER-2 • FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • AR expression • FOLH1 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 05/24/2021","start_date":" 05/24/2021","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-05-22"},{"id":"d5620614-b21c-4e48-b7e1-c4792175d95e","acronym":"APEX-01","url":"https://clinicaltrials.gov/study/NCT04662580","created_at":"2023-11-22T19:16:10.387Z","updated_at":"2024-07-02T16:35:04.424Z","phase":"Phase 1","brief_title":"ARX517 in Subjects With Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT04662580 - APEX-01","lead_sponsor":"Ambrx, Inc.","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • JNJ-8177"],"overall_status":"Recruiting","enrollment":" Enrollment 262","initiation":"Initiation: 07/27/2021","start_date":" 07/27/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2024-05-10"},{"id":"f99a8696-8fa3-4a88-8fbc-fa52c7ef12b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03089203","created_at":"2024-04-26T15:50:57.697Z","updated_at":"2024-07-02T16:35:07.388Z","phase":"Phase 1","brief_title":"CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer","source_id_and_acronym":"NCT03089203","lead_sponsor":"University of Pennsylvania","biomarkers":" TGFB1","pipe":" | ","alterations":" FOLH1 expression","tags":["TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CART-PSMA- TGFβRDN cells"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 03/08/2017","start_date":" 03/08/2017","primary_txt":" Primary completion: 09/08/2038","primary_completion_date":" 09/08/2038","study_txt":" Completion: 12/08/2038","study_completion_date":" 12/08/2038","last_update_posted":"2024-04-26"},{"id":"41e05d8d-ee7d-474e-b205-8af1be377e26","acronym":"","url":"https://clinicaltrials.gov/study/NCT04310540","created_at":"2021-01-18T20:53:53.861Z","updated_at":"2024-07-02T16:35:10.165Z","phase":"Phase 1","brief_title":"PSMA PET/MRI or PSMA PET/CT for Evaluation of Liver Cancer","source_id_and_acronym":"NCT04310540","lead_sponsor":"Mayo Clinic","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 06/05/2020","start_date":" 06/05/2020","primary_txt":" Primary completion: 11/02/2023","primary_completion_date":" 11/02/2023","study_txt":" Completion: 11/02/2023","study_completion_date":" 11/02/2023","last_update_posted":"2024-04-11"},{"id":"3a3871a3-373b-4120-a2fd-01f883ff6944","acronym":"","url":"https://clinicaltrials.gov/study/NCT06066437","created_at":"2023-10-04T15:10:45.245Z","updated_at":"2024-07-02T16:35:12.192Z","phase":"Phase 1/2","brief_title":"NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial","source_id_and_acronym":"NCT06066437","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Firmagon (degarelix)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 03/29/2024","start_date":" 03/29/2024","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-04-01"},{"id":"1bc7d467-7896-491d-8c0c-8c4bb935a5f1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03972657","created_at":"2023-08-08T17:08:39.649Z","updated_at":"2024-07-02T16:35:15.522Z","phase":"Phase 1/2","brief_title":"A Trial to Find Out if REGN5678 is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors","source_id_and_acronym":"NCT03972657","lead_sponsor":"Regeneron Pharmaceuticals","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • Kevzara (sarilumab) • nezastomig (REGN5678)"],"overall_status":"Recruiting","enrollment":" Enrollment 345","initiation":"Initiation: 08/12/2019","start_date":" 08/12/2019","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 07/03/2026","study_completion_date":" 07/03/2026","last_update_posted":"2024-03-08"},{"id":"49b9053e-073c-41d4-a526-b723982994d7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06209853","created_at":"2024-01-18T15:18:37.711Z","updated_at":"2024-07-02T16:35:23.032Z","phase":"","brief_title":"Role of F-18 PSMA in Prostate Cancer Patient","source_id_and_acronym":"NCT06209853","lead_sponsor":"Assiut University","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 59","initiation":"Initiation: 01/15/2024","start_date":" 01/15/2024","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-01-18"},{"id":"c2396d97-5dcb-4957-9af5-f11594ca099b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04762888","created_at":"2021-02-21T13:52:25.450Z","updated_at":"2024-07-02T16:35:23.055Z","phase":"Phase 2","brief_title":"68Ga-PSMA-Dual-Contrast PET/MRI or PET/CT for Early Detection of Liver Cancer","source_id_and_acronym":"NCT04762888","lead_sponsor":"Mayo Clinic","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression • FOLH1 overexpression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression • FOLH1 overexpression"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 02/24/2021","start_date":" 02/24/2021","primary_txt":" Primary completion: 01/10/2025","primary_completion_date":" 01/10/2025","study_txt":" Completion: 07/07/2025","study_completion_date":" 07/07/2025","last_update_posted":"2024-01-18"},{"id":"84f26417-2d13-4a35-a758-090ff959010c","acronym":"PRODIGY-1","url":"https://clinicaltrials.gov/study/NCT05896371","created_at":"2023-06-09T16:06:45.611Z","updated_at":"2024-07-02T16:35:28.408Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy","source_id_and_acronym":"NCT05896371 - PRODIGY-1","lead_sponsor":"CHU de Quebec-Universite Laval","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 01/29/2024","start_date":" 01/29/2024","primary_txt":" Primary completion: 06/15/2028","primary_completion_date":" 06/15/2028","study_txt":" Completion: 06/15/2032","study_completion_date":" 06/15/2032","last_update_posted":"2023-11-22"},{"id":"746925ad-4238-4014-a368-7392430557dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05656573","created_at":"2022-12-19T14:58:50.087Z","updated_at":"2024-07-02T16:35:29.865Z","phase":"Phase 1","brief_title":"CART-PSMA Cells for Advanced Prostate Cancer","source_id_and_acronym":"NCT05656573","lead_sponsor":"Nova Therapeutics LLC","biomarkers":" IFNG • IL6 • TNFA • IL2 • IL10","pipe":" | ","alterations":" FOLH1 expression","tags":["IFNG • IL6 • TNFA • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CART-PSMA"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-11-08"},{"id":"3d49c2e9-c873-459f-87ad-3ce24139ce28","acronym":"","url":"https://clinicaltrials.gov/study/NCT05603559","created_at":"2022-11-02T14:56:59.974Z","updated_at":"2024-07-02T16:35:32.151Z","phase":"Phase 1","brief_title":"177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer","source_id_and_acronym":"NCT05603559","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression • FOLH1 overexpression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression • FOLH1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 177Lu-P17-087 • 177Lu-P17-088"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 09/05/2023","primary_completion_date":" 09/05/2023","study_txt":" Completion: 10/04/2023","study_completion_date":" 10/04/2023","last_update_posted":"2023-10-23"},{"id":"0f494b10-c7de-444c-8668-530d6e3b1c05","acronym":"Trace-II","url":"https://clinicaltrials.gov/study/NCT05555017","created_at":"2022-09-26T14:56:17.853Z","updated_at":"2024-07-02T16:35:34.518Z","phase":"Phase 2","brief_title":"Tracer-Guided Surgery for Recurrent Prostate Cancer","source_id_and_acronym":"NCT05555017 - Trace-II","lead_sponsor":"The Netherlands Cancer Institute","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e triptorelin"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 02/15/2023","start_date":" 02/15/2023","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2023-10-06"},{"id":"9e1f8708-22b2-47e9-b865-3f81381b74c6","acronym":"NL78279.058.21","url":"https://clinicaltrials.gov/study/NCT05522257","created_at":"2022-08-31T16:59:04.959Z","updated_at":"2024-07-02T16:35:35.219Z","phase":"","brief_title":"PSMA Expression and PSMA PET Imaging in Soft Tissue Sarcomas and Urothelial Cell Carcinomas","source_id_and_acronym":"NCT05522257 - NL78279.058.21","lead_sponsor":"Leiden University Medical Center","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-09-29"},{"id":"ad8e2f02-0e18-4c7b-8135-37e6bbf194f3","acronym":"PRISMA","url":"https://clinicaltrials.gov/study/NCT06059469","created_at":"2023-09-28T14:10:36.853Z","updated_at":"2024-07-02T16:35:35.436Z","phase":"Phase 2","brief_title":"PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer.","source_id_and_acronym":"NCT06059469 - PRISMA","lead_sponsor":"Jules Bordet Institute","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/30/2022","start_date":" 05/30/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-09-28"},{"id":"314ad495-1e1d-4886-80b0-aac4727d35e4","acronym":"BOP","url":"https://clinicaltrials.gov/study/NCT05613842","created_at":"2022-11-14T15:57:14.900Z","updated_at":"2024-07-02T16:35:35.763Z","phase":"Phase 2","brief_title":"Copper-64 SAR Bombesin in PSMA Negative Prostate Cancer (BOP)","source_id_and_acronym":"NCT05613842 - BOP","lead_sponsor":"St Vincent's Hospital, Sydney","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 08/09/2022","start_date":" 08/09/2022","primary_txt":" Primary completion: 06/06/2023","primary_completion_date":" 06/06/2023","study_txt":" Completion: 06/06/2023","study_completion_date":" 06/06/2023","last_update_posted":"2023-09-26"},{"id":"5acfdf6a-fe0c-4e22-8bb5-edf1e5fc9fe1","acronym":"GIPSMA","url":"https://clinicaltrials.gov/study/NCT05547919","created_at":"2022-09-21T18:56:13.254Z","updated_at":"2024-07-02T16:35:37.266Z","phase":"","brief_title":"PSMA in Gastrointestinal Tumors (GIPSMA, Focusing on Neuroendocrine Neoplasms)","source_id_and_acronym":"NCT05547919 - GIPSMA","lead_sponsor":"Wuerzburg University Hospital","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 10/01/2022","start_date":" 10/01/2022","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2023-09-13"},{"id":"1b36b4ee-0095-44fb-b7a3-0681f98a1eb6","acronym":"ACTION","url":"https://clinicaltrials.gov/study/NCT05567770","created_at":"2022-10-05T12:55:59.042Z","updated_at":"2024-07-02T16:35:39.145Z","phase":"Phase 1","brief_title":"ACTInium-J591 Radionuclide Therapy in PSMA-Detected Metastatic HOrmone-Sensitive Recurrent Prostate CaNcer","source_id_and_acronym":"NCT05567770 - ACTION","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ac-225 rosopatamab tetraxetan (CONV01-α)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2030","study_completion_date":" 01/01/2030","last_update_posted":"2023-08-24"},{"id":"c80cf134-c02c-4a93-8bf8-d4cdb0927440","acronym":"","url":"https://clinicaltrials.gov/study/NCT05175404","created_at":"2022-01-03T15:00:45.734Z","updated_at":"2024-07-02T16:35:39.052Z","phase":"Phase 2","brief_title":"Use of 18F-PSMA-11 PET for Detection of Lesions in Iodine Refractory Thyroid Cancers","source_id_and_acronym":"NCT05175404","lead_sponsor":"University Hospital, Ghent","biomarkers":" TG","pipe":" | ","alterations":" FOLH1 expression","tags":["TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 01/24/2022","start_date":" 01/24/2022","primary_txt":" Primary completion: 07/18/2023","primary_completion_date":" 07/18/2023","study_txt":" Completion: 07/18/2023","study_completion_date":" 07/18/2023","last_update_posted":"2023-08-24"},{"id":"52ccfcca-1f05-482e-9040-fd003889afcc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05887687","created_at":"2023-06-05T15:07:18.167Z","updated_at":"2024-07-02T16:35:46.345Z","phase":"","brief_title":"68Ga-P3 PET/CT Imaging in Malignancy","source_id_and_acronym":"NCT05887687","lead_sponsor":"Peking University First Hospital","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 05/20/2023","start_date":" 05/20/2023","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2023-06-06"},{"id":"f50511c5-706c-42d0-bd3b-a710cf7dd9de","acronym":"","url":"https://clinicaltrials.gov/study/NCT05006326","created_at":"2021-08-16T16:54:32.694Z","updated_at":"2024-07-02T16:35:55.672Z","phase":"","brief_title":"Clinical Application of 68Ga-PSMA PET/MR for Diagnosis and Staging in Hepatocellular Carcinoma","source_id_and_acronym":"NCT05006326","lead_sponsor":"Wuhan Union Hospital, China","biomarkers":" AFP • FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["AFP • FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/16/2021","start_date":" 08/16/2021","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2023-02-14"}]